Saturday, April 11, 2026

 

Penn researchers use AI to surface unreported GLP-1 side effects in Reddit posts




An AI analysis of more than 400,000 Reddit posts found discussions of menstrual changes, fatigue and temperature-related complaints that may not be fully captured in clinical trials or drug labeling.




University of Pennsylvania School of Engineering and Applied Science

Analyzing Reddit Posts About GLP-1s with AI 

image: 

A close-up of the process the researchers used to analyze Reddit posts: at left is an example of the type of post the researchers fed into an AI-powered analysis, part of which is shown at right. 

view more 

Credit: Sylvia Zhang





By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.  

The new study, published in Nature Health, covers more than half a decade of posts from nearly 70,000 Reddit users and highlights two main classes of symptoms that warrant further study: reproductive symptoms, including irregular menstrual cycles, and temperature-related complaints, such as chills and hot flashes. 

“Some of the side effects we found, like nausea, are well known, and that shows that the method is picking up a real signal,” says Sharath Chandra Guntuku, Research Associate Professor in Computer and Information Science (CIS) at Penn Engineering and the study’s senior author. “The underreported symptoms are leads that came from patients themselves, unprompted, and clinicians could potentially pay attention to them.”  

“Clinical trials generally identify the most dangerous side effects of drugs,” adds Lyle Ungar, Professor in CIS and a co-author on the study. “But they can fail to find what symptoms patients are most concerned about; even though social media is not necessarily representative, a large collection of posts may reflect additional concerns.” 

The researchers caution that their findings are not causal. “We can’t say that GLP-1s are actually causing these symptoms,” notes Neil Sehgal, the study’s first author and a doctoral student in CIS advised by Guntuku and Ungar. “But nearly 4% of the Reddit users in our sample reported menstrual irregularities, which would be even higher in a female-only sample. We think that’s a signal worth investigating.” 

Studying Social Media for Health

In 2011, Ungar participated in one of the earliest efforts to mine online, user-created content for information about drugs’ adverse effects. 

“Online patient communities work a lot like a neighborhood grapevine,” says Ungar. “People who are living with these medications are swapping notes with each other in real time, sharing experiences that rarely make it into a doctor's office visit or an official report.”

In the years since, social media use has only grown, making data from these platforms increasingly promising as a source of information about the side effects of medications, even as the platforms themselves have made accessing the data more difficult. (Guntuku has also published research on strategies for adapting to changes in platform access.)

“Clinical trials are the gold standard, but by design, they are slow,” says Guntuku. “This is not a replacement for trials, but it can move much faster, and that speed matters when a drug goes from niche to mainstream almost overnight.” 

Leveraging AI to Analyze Social Media

Until now, the most challenging part of this process, which Guntuku calls "computational social listening,” has been scale. 

Because users vary in how they describe their symptoms, the effort required to map individual social media posts to language in the Medical Dictionary for Regulatory Activities (MedDRA),  which clinicians use to describe symptoms, limited the amount of data this approach could handle. 

Now, large language models like GPT or Gemini have enabled the systematic analysis of social media posts at unprecedented scale. “Large language models have made it possible to do this kind of analysis much faster with a level of standardization that could be difficult to achieve before,” says Sehgal. 

Unreported Symptoms 

While the population the researchers studied is admittedly not representative — Reddit users are younger, more likely to be male and disproportionately based in the United States — the symptoms described in their collective accounts largely match the known side effects of semaglutide and tirzepatide: about 44% of users in the study described at least one side effect, most commonly some form of gastrointestinal distress. 

What stood out was the nontrivial percentage of users who reported symptoms that may not be fully reflected in current drug labeling or routine adverse-event reporting. Nearly 4% of users who reported side effects described reproductive symptoms, including menstrual changes such as intermenstrual bleeding, heavy bleeding and irregular cycles. 

Others reported temperature-related complaints, such as chills, feeling cold, hot flashes and fever-like symptoms 

In addition, fatigue ranked as the second most common complaint among Reddit users, despite reaching reporting thresholds in relatively few clinical trials.

“These drugs are thought to work by engaging part of the brain called the hypothalamus, which helps regulate a wide variety of hormones,” says Jena Shaw Tronieri, Senior Research Investigator at Penn’s Center for Weight and Eating Disorders and a co-author of the study. “That doesn’t mean the medications are necessarily causing these symptoms, but it could suggest that reports of menstrual changes and body temperature fluctuations are worth studying more systematically.” 

Future Directions

In the near term, the researchers hope their findings will encourage clinicians and researchers to take a closer look at the side effects patients are discussing online. “They’re clearly on patients’ minds, and that’s worth paying attention to,” says Sehgal.

The team also hopes to expand the work beyond Reddit and beyond English-language communities to test whether the same patterns appear across different platforms and populations. 

“We don’t really know yet whether what we’re seeing on Reddit reflects the experience of GLP-1 users globally, or whether it’s particular to the kind of person who posts on Reddit in the United States,” Ungar says. 

Ultimately, the researchers believe this kind of rapid, AI-assisted social media analysis could become a useful way to spot early warning signs around emerging drugs and wellness trends. 

For substances that trend quickly online, especially those sold in loosely regulated or unregulated markets, like injectable peptides, patient discussions on platforms like Reddit and TikTok may offer one of the earliest clues to what users are actually experiencing. 

“The whole point of this kind of approach is that it can move quickly, and that’s exactly when it’s most valuable,” says Guntuku.

This study was conducted at the University of Pennsylvania School of Engineering and Applied Science. The authors report no outside funding. Tronieri reports receiving an investigator-initiated grant, on behalf of the University of Pennsylvania, from Novo Nordisk and receiving consulting fees from Currax Pharmaceuticals, LLC. The other authors report no conflicts of interest. 


A close-up of the process the researchers used to analyze Reddit posts: at left is an example of the type of post the researchers fed into an AI-powered analysis, part of which is shown at right. 

Credit

Sylvia Zhang

AI gives doctors early warning of disease “tipping points” — often from a single patient sample



New Intelligent Medicine editorial details how dynamics-driven models are enabling real-time, individualized disease forecasting




Intelligent Medicine






The editorial, "Dynamics-driven medical big data mining: dynamic approaches to early disease forecasting and individualized care," published in Intelligent Medicine (February 2026, Volume 6, Issue 1), was written by Lu Wang (Tianjin Medical University), Han Lyu (Beijing Friendship Hospital, Capital Medical University), and Bin Sheng (Shanghai Jiao Tong University). It argues that the future of medical AI lies not only in diagnosing disease once it is visible, but in detecting the early dynamic changes that happen before symptoms fully appear. By analyzing how health data evolve over time, from omics and medical records to imaging and wearable devices, AI may help identify “tipping points” when the body is moving toward disease. The authors also stress that these systems must be rigorously validated and used to support, not replace, clinical judgment.

 

From population averages to individual tipping points

At the heart of this framework is dynamic network biomarker (DNB) theory, which detects impending disease transitions by monitoring sharp rises in fluctuations and correlations within biomolecular networks. Prior work summarized in the editorial has validated DNB-based approaches across two clinically important scenarios: flagging heightened gene-expression instability in influenza infection days before symptoms appear, and identifying genomic tipping points where cells shift from benign to malignant states, with tumor progression prediction accuracies exceeding 80%.

For busy clinicians, the most immediately relevant advance may be individual-specific edge-network analysis (iENA), which transforms molecular data into edge networks and assesses critical transitions using a single patient's own longitudinal data, without requiring a control group. In transcriptomic applications, this single-sample approach has achieved area-under-the-curve (AUC) values greater than 0.9, bringing real-time, bedside-applicable dynamic assessment within reach for the first time in this class of methods.

 

Hybrid AI narrows the gap between models and patients

The editorial also presents evidence that combining mechanistic physiological knowledge with deep learning, rather than relying on data-driven models alone, substantially improves clinical utility. In type 1 diabetes management, physiology-informed long short-term memory (LSTM) networks reduced mean absolute error in blood-glucose prediction to 35.0 mg/dL, compared with 79.7 mg/dL for traditional simulators, achieving a reduction of more than 55%. These models create patient-specific digital twins that can be used to test therapeutic strategies in silico before clinical application.

Beyond metabolic disease, the editorial describes parallel advances across data modalities: temporal graph neural networks applied to EHRs improved diagnosis prediction accuracy by 10–15% on the MIMIC-III dataset; dynamic graph models derived from functional MRI predicted treatment outcomes in tinnitus; and Transformer-based architectures trained on longitudinal EHRs have shown capacity to forecast multi-disease risks, including diabetes and hypertension, through hierarchical attention mechanisms.

 

Augmenting, not replacing, clinical judgment

"These dynamics-driven approaches are designed to augment, not replace, clinical expertise," said Professor Bin Sheng, corresponding author and professor at the School of Computer Science, Shanghai Jiao Tong University. "They provide timely early-warning signals that empower proactive intervention, moving medicine from reactive treatment to genuine prevention, while preserving the irreplaceable role of human judgment in complex medical decision-making."

 

Current limitations demand careful deployment

The editorial is equally direct about the challenges that must be resolved before these tools can deliver equitable, real-world benefits. Data heterogeneity and missing values can produce false positives in critical transition detection, inflating network fluctuations in ways that generate erroneous alerts. A more fundamental challenge is that current methods excel at identifying statistical associations but cannot reliably distinguish correlation from causation without incorporating medical domain knowledge and experimental validation. Interpretability remains a significant barrier: although tools such as SHAP and LIME provide partial explanations for model decisions, full transparency in deep architectures is yet to be achieved, and opaque predictions risk eroding the clinical trust that adoption requires.

Ethical and regulatory concerns also demand attention. Privacy risks persist in federated learning despite distributed training architectures, and algorithmic bias is a particular concern when models trained on specific populations are deployed in underrepresented groups, with the potential to widen rather than narrow healthcare inequalities.
 

The path forward: multimodal integration and prospective validation

Looking ahead, the editorial identifies two priorities. The first is multimodal integration: fusing omics, imaging, EHR, and wearable data through advanced Transformers, graph neural networks, and causal inference methods, including instrumental variables and counterfactual simulations, to construct comprehensive, causal models of individual disease trajectories. The second, and arguably more critical, is rigorous prospective validation. The authors stress that the gap between theoretical promise and clinical implementation can only be closed through well-designed prospective clinical trials and real-world deployment studies across diverse populations and healthcare settings.

Published as open access, the editorial serves as both a state-of-the-field reference and a practical roadmap for clinicians, researchers, and healthcare leaders working at the intersection of medicine and artificial intelligence.

 

***

 

Reference
DOI: 10.1016/j.imed.2025.10.001
 

About the Corresponding Author
Professor Bin Sheng received his Ph.D. in Computer Science and Engineering from The Chinese University of Hong Kong in 2011. He currently serves as a full professor at the School of Computer Science of Shanghai Jiao Tong University. His research focuses on virtual reality, computer graphics, and medical artificial intelligence. Sheng has published extensively in leading journals, including JAMA, Nature Medicine, The Lancet Digital Health, and IEEE Transactions on Pattern Analysis and Machine Intelligence. He is the Managing Editor of The Visual Computer and has co-chaired multiple international conferences and AI challenges.


About the Journal
Intelligent Medicine is a peer-reviewed, open-access journal focusing on the integration of artificial intelligence, data science, and digital technology in clinical medicine and public health. It is published by the Chinese Medical Association in partnership with Elsevier. To learn more about Intelligent Medicine, please visit: https://www.sciencedirect.com/journal/intelligent-medicine


Funding information
This work was supported by the Youth Fund of the National Natural Science Foundation of China (Grant No. 32300519, 62522119, and T2525004).

 

Pharma.AI Spring Kickoff 2026: Drive the future of pharmaceutical intelligence




InSilico Medicine
Pharma.AI Spring Kickoff 2026: Drive the Future of Pharmaceutical Intelligence 

image: 

As the AI era becomes increasingly shaped by foundation models, the pharmaceutical industry is entering a new phase of opportunity for discovery, design, and decision-making driven by AI for science. To explore these advancements, Insilico Medicine (03696.HK), a clinical-stage generative AI–driven drug discovery company, today announced that the Pharma.AI Spring Kickoff 2026 will be held at 10:00 AM ET on April 14, with registration and event details available at: https://insilico.zoom.us/webinar/register/WN_h7tujok6SdmfDWzkZwRgNg.

view more 

Credit: Insilico Medicine




As the AI era becomes increasingly shaped by foundation models, the pharmaceutical industry is entering a new phase of opportunity for discovery, design, and decision-making driven by AI for science. To explore these advancements, Insilico Medicine (03696.HK), a clinical-stage generative AI–driven drug discovery company, today announced that the Pharma.AI Spring Kickoff 2026 will be held at 10:00 AM ET on April 14, with registration and event details available at: https://insilico.zoom.us/webinar/register/WN_h7tujok6SdmfDWzkZwRgNg.

The 2026 season of the Pharma.AI webinar series will showcase the ongoing AI revolution in life sciences, including the increased interest in the use of foundation models why specialized models remain essential for biology, chemistry, and translational research; How Pharma.AI brings together foundation models and scientific AI agents within a unified AI-driven workflow for drug R&D and scientific research; and how Insilico’s leading “AI trains AI” approach may enable foundation models to be better adapted for scientific and drug discovery applications, accelerating the evolution of AI decision-making systems.

More specifically, the upcoming event will highlight new capabilities across the Pharma.AI ecosystem, including the MMAI Gym for Science, updates to core modules such as PandaOmics, Generative Biologics, and Chemistry42.

"As we kick off 2026, our focus is on moving beyond simple AI-driven toward a truly AI-decision ecosystem," says Alex Aliper, PhD, president at Insilico Medicine. "With the introduction of the continued evolution of Pharma.AI, we are building the foundation for pharmaceutical superintelligence systems that can reason more effectively, adapt to real scientific workflows, and generate meaningful impact across drug discovery and development. The upcoming webinar brings together exciting new updates and is designed to provide researchers with the latest tools and best practices for tackling the most challenging problems in human health."

 

Highlights at a Glance

  • MMAI Gym: Turning Foundation Models into High-Performance Drug Discovery Engines

The MMAI Gym for Science, a foundation model training framework, was introduced by Insilico in January 2026. Leveraging over 1,000 drug R&D benchmarks and approximately 120 billion tokens of public and proprietary drug discovery data, the framework utilizes multi-task fine-tuning and reinforcement learning to significantly enhance the performance of foundation models across specialized tasks in drug discovery.

Validating the power of this framework, we demonstrate that MMAI-trained foundation models achieved up to 10X performance gains on key drug discovery benchmarks compared to general-purpose foundation models, which fell short on approximately 75–95% of tasks. Moreover, in March 2026, Insilico and Liquid AI jointly delivered LFM2-2.6B-MMAI (v0.2.1), the first model trained through their first MMAI Gym collaboration. Despite its lightweight, on-premise design, the model delivered SOTA performance across several key tasks. The paper detailing the training process and final performance was accepted at ICLR 2026.

During the upcoming event, attendees will learn how this supervised fine-tuning (SFT) and reinforcement fine-tuning (RFT) training and benchmarking system can significantly improve the performance of causal LLMs on real-world drug discovery tasks, and how to access the platform.

  • PandaOmics: Target Prioritization with Single-Cell and PandaClaw

PandaOmics is Insilico Medicine’s AI-driven platform for therapeutic target discovery and indication expansion. It integrates and analyzes large-scale multi-omics and biomedical datasets to help researchers to identify and prioritize disease-specific drug targets and to expand the therapeutic indications of targets of interest.

Recent upgrades to PandaOmics include the incorporation of comprehensive single-cell datasets, which provide enhanced resolution for target identification. In addition, PandaClaw, an agentic AI tool that allows scientists to conduct complex, real-time multi-omics analyses, generate research hypotheses, and perform target evaluations via a simple natural-language interface.

  • Chemistry42: Multi-Target and Advanced Alchemistry

Chemistry42 is Insilico Medicine’s AI-driven platform for designing and discovering novel small molecules. It combines generative model ensembles and advanced physics-based methods to help researchers create and optimize novel compounds. A core part of Chemistry42 is Nach01, an AI model trained on billions of data points to understand both natural and chemical language, enabling hundreds of professional tasks and laying the groundwork for a “prompt-to-drug” future.

The latest updates include multitarget support for molecule generation, enhanced results visualization for smoother analysis, Nach01-MMAI for molecule generation, and new Absolute Binding Free Energy (ABFE) calculations in Alchemistry.

  • Generative Biologics: Cyclic Peptide Design & Linear Peptide Optimization

Generative Biologics is a cutting-edge biologics engineering platform. It uses advanced multi-parameter optimization to tackle complex challenges in the design of antibodies, peptides, and other biologic drugs. Powered by more than 10 generative and predictive models and enhanced by precise physics-based tools, Generative Biologics enables the rapid creation of diverse, optimized biologics, allowing scientists to generate viable binder candidates in less than 72 hours.

The platform now includes major updates for peptide design. It introduces a completely new workflow for cyclic peptides, supporting both head-to-tail and disulfide-bond architectures, generating hundreds of candidates in just hours with AI- and physics-based prioritization. In parallel, researchers have successfully optimized linear peptides using the platform to refine the lead candidate, P3, against GLP-1R and to produce dozens of new candidates, with the top variant, P3-1, achieving a sixfold improvement over the original lead.

Pharma.AI is an end-to-end AI platform for drug discovery and development, integrating target discovery, generative chemistry, biologics design, and predictive clinical modeling into a unified AI-driven workflow for pharmaceutical R&D. We hope to see you at our first event as we kick off 2026.

 

Date: April 14, 2026

Time: 10:00 AM ET

Link: Register via Zoom

 

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com

Artificial intelligence driven controllers imitating the human brain could strengthen the grid



A new study at the University of Vaasa, Finland, introduces advanced AI-based control strategies that ensure local grids remain reliable and resilient



University of Vaasa

Hussain Khan 

image: 

Hussain Khan

view more 

Credit: Photo: University of Vaasa





As traditional power plants are replaced by intermittent sources like solar and wind, maintaining grid stability has become a complex engineering challenge. Hussain Khan’s doctoral dissertation at the University of Vaasa, Finland, introduces advanced AI-based control strategies that ensure local grids remain reliable and resilient.

Power systems are undergoing a profound transformation as fossil-based generation is gradually replaced by inverter-based renewable energy. This shift introduces inherent uncertainty and low inertia, making grid operation and voltage stability significantly more complex in AC and DC microgrids.

In his dissertation in electrical engineering, Hussain Khan addresses these challenges. By utilising Artificial Neural Networks (ANN), Khan has developed controllers that can predict and compensate to grid changes in real-time, outperforming traditional control methods.

– ANNs inspired by the human brain, which processes information through interconnected neurons. This biomimetic approach allows the system to learn from diverse scenarios and adapt to the unpredictability of solar and wind power, says Khan.

Cost-effective solutions through sensor optimisation

Traditional systems rely on multiple physical sensors to monitor voltage, current, and other parameters, adding to costs and increasing the number of potential failure points. Khan’s AI-driven approach demonstrates that sophisticated software can compensate for fewer hardware components.

– By training the neural network effectively, the system can provide the same reliable results with only a single sensor instead of two. This leads to cost optimisation and improves overall reliability, as there are fewer physical parts that could fail, Khan notes.

While AI-based control can improve efficiency and reduce hardware requirements, introducing intelligent controllers into critical infrastructure also raises new considerations.

– The main concern is that AI works like a black box: we can see the inputs and outputs, but not always fully explain what is happening inside. Even so, in our tests the controller performed very well and was validated rigorously in real time, notes Khan.

Khan’s research supports the broader goal of building carbon-neutral energy systems in the coming decades. By improving stability and reducing hardware requirements, AI-based control could help electricity grids integrate larger shares of renewable energy in the future.

Dissertation

Khan, Hussain (2026) Advanced Predictive and AI-Based Converter Control Strategies for AC and DC Microgrids. Acta Wasaensia 580. Doctoral dissertation. University of Vaasa.

Publication PDF

 

Artificial intelligence and drones to select the most resilient wheat



A study led by the University of Barcelona and Agrotecnio presents a new strategy for identifying wheat varieties that are more productive and better adapted to climate change




University of Barcelona

Artificial intelligence and drones to select the most resilient wheat 

image: 

The team analysed 64 varieties of durum wheat grown under two different Mediterranean conditions: irrigated and rain-fed.

view more 

Credit: Jara Jauregui-Besó (University of Barcelona - AGROTECNIO)





Making wheat more resilient to climate change without compromising yields has become an urgent priority for the agricultural sector. Now, a study led by a research team from the University of Barcelona and the Agrotecnio research centre has identified an innovative way to address this challenge: combining advanced technology and artificial intelligence to select the best varieties of this crop.

The study, published in the journal Plant Phenomics, suggests a shift in perspective: it is necessary to focus not only on yield, but also on wheat’s ability to maintain consistent harvests despite changing weather conditions. The findings indicate that this combination of productivity and stability is key to ensuring safe harvests under variable environmental conditions.

The authors of the study are researchers Jara Jauregui, José Luis Araus and Shawn Carlisle Kefauver, from the Department of Evolutionary Biology, Ecology and Environmental Sciences at the UB’s Faculty of Biology and Agrotecnio; Nieves Aparicio and Sara Álvarez, from the Agro-technological Institute of Castilla y León (ITACyL), and María Teresa Nieto, from the National Institute for Agricultural and Food Research and Technology (INIA-CSIC).

Drones for monitoring wheat crops

The team analysed 64 varieties of durum wheat grown under two different Mediterranean conditions: irrigated and rain-fed. The aim was to identify which genotypes combine high yields with a stable performance across variable environments, with differences in temperature and water availability.

One of the most surprising findings is that the selected varieties are not those that retain their green leaves the longest until the end of the season, but rather those that grow vigorously at the start and mature slightly earlier.

In contrast, the rejected lines showed low initial vigour and retained their green leaves for longer, which does not guarantee a better yield.

As part of the project, the team used ground-sensors and drones equipped with RGB, multispectral and thermal cameras, enabling them to monitor crop development throughout the entire growing cycle. This technology provides key information about the wheat before harvesting, eliminating the need for harvesting and reducing both the costs and the time required for analysis.

Using all this data, the team trained artificial intelligence models capable of predicting both the yield and the stability of production for the different varieties with a high degree of accuracy.

This strategy could be a very useful tool for plant breeding programmes and could help develop wheat varieties that are equipped to meet the challenges of climate change.

Greener doesn’t always mean better

The researchers first analysed, separately, the yield and stability traits of durum wheat. They found that the genotypes with the highest yields are characterised by high initial vigour and sustained greenness during the rapid growth phases up to the end of the growing season. In contrast, the most stable genotypes exhibit lower initial vigour, slower growth and a shorter cycle, enabling them to make better use of the resources available for grain production. To identify a balance between these compensatory mechanisms, the experts developed a variety selection method that combines competitive yield with good stability.

The study concludes that vigorous early growth combined with early maturation is a key factor to achieving more consistent yields under variable environmental conditions, helping wheat cope better with drought and high temperatures.

 

 

Lancet Countdown Europe: New report on health and climate change



Experts from academia, practice and policy explain the dramatic health impacts of the climate crisis and discuss successful climate action and health protection




Heidelberg University






Europe’s dependence on fossil fuels is not only making the continent economically and politically vulnerable, it also has dramatic consequences for the population’s health. Growing air pollution, heat damage and the climate-related spread of infectious diseases are looming, warns the 2026 Europe Report of the Lancet Countdown on Health and Climate Change, which its co-directors Prof. Dr Joacim Rocklöv (Heidelberg University) and Prof. Dr Cathryn Tonne (Barcelona Institute for Global Health) are about to present to the public. Together with other experts from academia, practice and policy they will discuss the report’s results during a public event at Heidelberg University, comparing the current findings with successful measures for climate action and health protection. The launch event with livestreaming is to take place on 22 April 2026.

The Lancet Countdown Europe is an interdisciplinary research collaboration made up of 65 experts from research institutions and United Nations organizations. Established in 2021 as a regional center of the global Lancet Countdown, the collaboration tracks the connections between health and climate change in Europe across five domains. These include health risks and impacts, adaptation and mitigation action taken, the areas of economy and finance, and engagement with climate change and health across societal actors. The third Europe report, which will be published in the journal “Lancet Public Health”, presents a total of 43 indicators.

“We are seeing very clearly that fossil-fuel driven climate change constitutes a growing threat to the health of an ever greater number of people in Europe,” Prof. Rocklöv underlines. But at the same time, he adds, there are also positive examples from climate action and health protection. “A host of steps being taken nationally and locally allow us to hope that the climate crisis can be contained and its impacts reduced,” says the epidemiologist, mathematician, and statistician, who, as an Alexander von Humboldt Professor at Heidelberg University, conducts research in a number of large-scale projects at the university and Heidelberg University Hospital on the impacts of climate and environmental change on public health. Since 2024, together with Prof. Tonne, he has co-chaired the research collaboration of the Lancet Countdown Europe.

The Dean of the Medical Faculty Heidelberg of Heidelberg University, Prof. Dr Michael Boutros, will open the launch event for the 2026 Europe Report of the Lancet Countdown on Health and Climate Change. Then Prof. Rocklöv and Prof. Tonne will present the main results. Some of the success stories in climate action and health protection will follow, with speakers Aleksandra Kazmierczak, who is both coordinator of the European Climate and Health Observatory and the European Environment Agency’s climate and health expert, and Francesca Racioppi, head of the World Health Organization’s European Centre for Environment and Health. Experts from the Robert Koch Institute (Germany), the Austrian Competence Centre for Climate and Health, and the Agence Nationale de Santé Publique (France) will comment on the findings and report on ways in which their countries have responded to, for example, cases of climate-related infectious diseases, which have been rising rapidly in the past years. A panel discussion with federal, state, and local policy-makers will focus on how measures for climate action and health protection can be successfully implemented.

The event on 22 April will take place in the Great Hall of the Old University (Grabengasse 1, Heidelberg) and also be livestreamed, starting at 1pm. The interested public is also invited. Those attending in the Great Hall must take their seats by 12.45pm. The launch event will be in English with simultaneous interpretation into German for those attending in person. Attendance – both in person and online – requires registration at https://pretix.eu/uni-heidelberg/lcde-rp-2026